<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="200424">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00481091</url>
  </required_header>
  <id_info>
    <org_study_id>M06-873</org_study_id>
    <secondary_id>2007-002143-25</secondary_id>
    <nct_id>NCT00481091</nct_id>
  </id_info>
  <brief_title>A Phase 1/2a Study of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of
      ABT-263 under two different dosing schedules with the objective of defining the dose
      limiting toxicity and maximum tolerated dose. The Phase 2a portion of the study will
      evaluate ABT-263 at the defined recommended Phase 2 dose to obtain additional safety
      information and a preliminary assessment of efficacy. The Extension Study portion will allow
      active subjects to continue to receive ABT-263 for up to 7 years after the last subject
      transitions with less frequent study evaluations.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of dose limiting toxicity (DLT) and maximum tolerated dose (MTD)</measure>
    <time_frame>14 days on therapy and 7 days off therapy OR 21 days continuous dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile evaluation</measure>
    <time_frame>Repeating sequence of 14 days on therapy and 7 days off therapy OR 21 days of continuous dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy assessment (Phase 2a)</measure>
    <time_frame>Repeating cycles of 21 days continuous dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment</measure>
    <time_frame>Repeating sequence of 14 days on therapy and 7 days off therapy OR 21 days of continuous dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm NA, Group is Applicable</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group/Cohort Number or Label is numerical and sequential starting with dose level 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-263</intervention_name>
    <description>Phase 1 dosing under two different schedules: 14 days on drug, 7 days or (14/21) or continuous dosing.
Phase 2a dosing at the recommended phase 2a dose and schedule</description>
    <arm_group_label>Arm NA, Group is Applicable</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed or refractory Chronic Lymphocytic Leukemia and require treatment in opinion
             of investigator

          -  Eastern Cooperative Oncology Group (ECOG) &lt;= 1

          -  Adequate bone marrow independent of growth factor support, renal and hepatic function
             per defined laboratory criteria

        Exclusion Criteria:

          -  History or clinically suspicious for cancer-related Central Nervous System disease

          -  Receipt of allogenic or autologous stem cell transplant

          -  Recent history (within 1 year of first dose) of underlying, predisposing condition of
             bleeding or currently exhibits signs of bleeding

          -  Active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis

          -  Active immune thrombocytopenic purpura or history of being refractory to platelet
             transfusions (within 1 year of first dose)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mack Mabry, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center, US /ID# 5566</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute /ID# 5547</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center /ID# 12261</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital /ID# 12267</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas - MD Anderson Cancer Center /ID# 5575</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties, PLLC /ID# 26428</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre /ID# 6583</name>
      <address>
        <city>East Melbourne</city>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital /ID# 5576</name>
      <address>
        <city>Parkville, Melbourne</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Koln /ID# 5924</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary, Univ Hosp of Leicester NHS /ID# 15081</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 7, 2017</lastchanged_date>
  <firstreceived_date>May 30, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Navitoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
